Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era

Michael Butzner; Douglas L Leslie; Yendelela Cuffee; Christopher S Hollenbeak; Christopher Sciamanna; Theodore Abraham

doi:10.3389/fcvm.2021.765876

Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era

Front Cardiovasc Med. 2022 Jan 6:8:765876. doi: 10.3389/fcvm.2021.765876. eCollection 2021.

Authors

Michael Butzner¹, Douglas L Leslie¹, Yendelela Cuffee^{1

2}, Christopher S Hollenbeak³, Christopher Sciamanna^{1

4}, Theodore Abraham⁵

Affiliations

¹ Department of Public Health Sciences, Pennsylvania State College of Medicine, Hershey, PA, United States.
² Program in Epidemiology, University of Delaware College of Health Sciences, Newark, DE, United States.
³ Department of Health Policy and Administration, Pennsylvania State University, University Park, PA, United States.
⁴ Department of Medicine, Pennsylvania State College of Medicine, Hershey, PA, United States.
⁵ Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.

Abstract

Hypertrophic cardiomyopathy is the most common genetic heart disease in the US, with an estimated prevalence of 1 in 500. However, the extent to which obstructive hypertrophic cardiomyopathy is clinically recognized is not well-established. Therefore, the objective of this study was to estimate the annual prevalence of clinically diagnosed oHCM in the US from 2016 to 2018. Data from the MarketScan® database were queried from years 2016 to 2018 to identify patients with ≥1 claim of oHCM (International Statistical Classification of Disease and Related Health Problems diagnosis code: I42.1). Prevalence rates for oHCM were calculated and stratified by sex and age. In 2016, 4,612 unique patients had clinical diagnosis of oHCM, resulting in an estimated oHCM prevalence of 1.65 per 10,000. The prevalence of oHCM in males and females was 2.07 and 1.26, respectively. Prevalence of oHCM was highest in patients 55-64 years of age (4.82). Prevalence of oHCM generally increased with age, from 0.36 per 10,000 in those under 18 to 4.82 per 10,000 in those 55-65. Trends in prevalence of oHCM over time, including by sex and age group, remained similar and consistent in 2017 and 2018. The prevalence of oHCM was stable over the 3-year time period, including higher rates of oHCM in males and patients aged 55-64 years. These results suggest that the majority of privately insured patients with oHCM are undiagnosed in the US and reinforce the need for policies and research to improve the clinical identification of oHCM patients in the US.

Keywords: age; claims data; hypertrophic cardiomyopathy; obstructive hypertrophic cardiomyopathy; prevalence; sex.